The coexistence of psoriasis with autoimmune bullous diseases (AIBDs), particularly bullous
pemphigoid (BP), has been documented in case reports and series, as well as in …

Objective This study aimed to investigate the clinical features of biologics-induced bullous
pemphigoid (BP) and the therapeutic effects of those agents for BP, exploring the underlying …

Biological agents are widely used across medicine, including for immune‐mediated skin
conditions such as psoriasis and atopic dermatitis. When used to treat a relevant …

Background Atopic dermatitis (AD) and psoriasis vulgaris (PV) are almost mutually exclusive
diseases with different immune polarizations, mechanisms and therapeutic targets. Switches …

Bullous pemphigoid (BP), the most common autoimmune blistering disease, is characterized
by the presence of autoantibodies targeting BP180 and BP230 in the basement membrane …

Current genome-wide association studies (GWAS) of plasma proteomes provide additional
possibilities for finding new drug targets for inflammatory dermatoses. We performed …

Biological drugs, including IL‐17A inhibitors, have become the first‐line treating options for
moderate to severe psoriasis, and reports show a beneficial effect of IL‐17A inhibitors on …

Abstracts Background and objective Biologics have revolutionized the management of
plaque psoriasis and are flourishing. We aimed to construct a knowledge structure in this …

Ustekinumab is a biological therapy that has been approved for treating moderate-to-severe
psoriasis. Although injection site reactions, nasopharyngitis, headaches, and infections are …

The development of targeted therapies for atopic diseases, urticaria, and angioedema with
biologics is progressing rapidly: New “targets” of clinical-therapeutic relevance have been …